Inactive

The Centers for Disease Control and Prevention intends to modidfy contract 75D30122C13551 with Biobot Analytics for wastewater testing. The original contract provides SARS-CoV-2 and Mpox wastewater su... The Centers for Disease Control and Prevention intends to modidfy contract 75D30122C13551 with Biobot Analytics for wastewater testing. The original contract provides SARS-CoV-2 and Mpox wastewater surveillance testing to 500 wastewater treatment facilities nationwide. For each enrolled wastewater facility, the contract provides twice weekly quantitative SARS-CoV-2 and Mpox testing and once weekly SARS-CoV-2 sequencing for variant tracking. The contract includes wastewater sampling supplies and sample shipping supplies for enrolled facilities and covers the cost of shipping. Data is submitted directly to CDC at least twice per week for use in the COVID response. This modification will continue Mpox and SARS-CoV-2 testing from the end of the current CLIN to the end of the contract in order to avoid any lapse in service while the new contract is being solicited. No changes will be made to the sampling sites, frequency, or duration of the sampling period. The testing results will be submitted to directly to CDC to be used by the Mpox and SARS-CoV-2 responses at CDC and state and local health departments. This notice of intent is not a request for competitive quotations. Any response should be emailed to William Brannen at VWL0@cdc.gov by 10:00 A.M. EST., July 18, 2023.